Quoin Pharmaceuticals Ltd. announced that it is initiating a second clinical trial in Netherton Syndrome patients. This multicenter, open label study will be being conducted under Quoin's currently open U.S. Investigational New Drug (IND) Application and will assess QRX003 topical lotion in Netherton patients who are currently receiving treatment including systemic therapy for symptomatic relief. QRX003 will be applied once daily over a twelve-week period, to pre- designated areas of the patient's body.

A number of different clinical endpoints will be assessed in the study. The active ingredient in QRX003 is a broad-spectrum serine protease inhibitor, whose mechanism of action is intended to down-regulate the hyperactivity of skin kallikreins, leading to a more normalized rate of skin shedding. If proven to be safe and effective, long term daily application of QRX003 could lead to the development of a more normally functioning skin barrier and a significant improvement in the quality of life of Netherton patients.